Last reviewed · How we verify
Adenocarcinoma of pancreas
Approved treatments
- Carac · Spectrum Pharms
- Gemcitabin · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Gemzar · Accord Hlthcare
Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression. - Mitozytrex · Kyowa Kirin Co., Ltd.
- Gemzar · Accord Hlthcare
Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process. - Camptosar · Pfizer
Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks. - Carac · Extrovis
- Camptosar · Pfizer
Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing. - Tarceva · Osi Pharms
Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow. - Camptosar · Pfizer
Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death. - Tarceva · M.D. Anderson Cancer Center
Clinical guidelines
- FDA label — 1L
Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. - FDA label — 1L
Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. - FDA label — 1L
Erlotinib in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Adenocarcinoma of pancreas patent landscape — cliff calendar, originator estates, attackable patents
- Adenocarcinoma of pancreas treatment landscape brief
- Adenocarcinoma of pancreas treatment updates RSS
Frequently asked questions about Adenocarcinoma of pancreas
What drugs treat Adenocarcinoma of pancreas?
Tracked treatments include Carac, Gemcitabin, Gemzar, Mitozytrex, Camptosar, Tarceva.
What is the treatment for Adenocarcinoma of pancreas?
Standard treatment for Adenocarcinoma of pancreas includes Carac, Gemcitabin, Gemzar, Mitozytrex, Camptosar. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Adenocarcinoma of pancreas?
FDA label publishes guidelines for Adenocarcinoma of pancreas. 3 guideline references tracked.
Related
- Treatment landscape: Adenocarcinoma of pancreas patent cliff · Adenocarcinoma of pancreas CI report
- Treatment: Carac · Spectrum Pharms
- Treatment: Gemcitabin · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Treatment: Gemzar · Accord Hlthcare
- Treatment: Mitozytrex · Kyowa Kirin Co., Ltd.
- Treatment: Gemzar · Accord Hlthcare
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing